Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Effect of “Methotrexate” and “Melphalan” on the Survival of Tumour and Skin Homo-grafts

Abstract

SEMI-ISOLOGOUS (F1 hybrid) mice surviving systemic leukæmia L1210 after extensive therapy with halogenated derivatives of ‘Methotrexate’ (MTX) were shown to be immune to re-inoculation with sensitive or resistant sub-lines of leukæmia L12101–3. In other work4–6, it was observed that MTX therapy of mice bearing homografts of MTX-resistant leukæmias abrogated the immune response. However, in a system involving differences at the strong H-2 histocompatibility locus, pretreatment of mice with MTX failed to promote the growth of L12107. In the latter system, pretreatment with a number of alkylating agents (cyclophosphamide, triethylene melamine, and ‘Melphalan’) and X-irradiation resulted in marked immune suppression. In view of the foregoing results, and the observation that MTX therapy did not interfere appreciably with the ability of an inoculum of splenic tissue to render mice immune to L12105, we decided to determine what effect a dose-level of MTX capable of abrogating the immune response to tumour homograft would have on the survival of skin homografts. Also, as part of the same experiment, the effect of pro-treatment with MTX on the immune response to skin and tumour homografts was determined, since, in the present system, only minor histocompatibility differences were involved. ‘Melphalan’, a potent immune suppressor7, was used as a positive control.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Goldin, A., Humphreys, S. R., Chapman, G. O., Chirigos, M. A., and Venditti, J. M., Nature, 185, 219 (1960).

    Article  ADS  CAS  Google Scholar 

  2. Goldin, A., and Humphreys, S. R., J. Nat. Cancer Inst., 24, 283 (1960).

    PubMed  CAS  Google Scholar 

  3. Goldin, A., Humphreys, S. R., Venditti, J. M., and Mantel, N., J. Nat. Cancer Inst., 22, 811 (1959).

    PubMed  CAS  Google Scholar 

  4. Potter, M., and Haas, V. H., J. Nat. Cancer Inst., 22, 801 (1959).

    PubMed  CAS  Google Scholar 

  5. Humphreys, S. R., Chirigos, M. A., Milstead, K. L., Mantel, N., and Goldin, A., J. Nat. Cancer Inst., 27, 259 (1961).

    PubMed  CAS  Google Scholar 

  6. Humphreys, S. R., Glynn, J. P., Chirigos, M. A., and Goldin, A., J. Nat. Cancer Inst., 28, 1053 (1962).

    PubMed  CAS  Google Scholar 

  7. Humphreys, S. R., Glynn, J. P., and Goldin, A., Transplantation, 1, 65 (1963).

    Article  CAS  Google Scholar 

  8. Friedkin, M., Crawford, E., Humphreys, S. R., and Goldin, A., Cancer Res., 22, 600 (1962).

    CAS  Google Scholar 

  9. Billingham, R. S., and Medawar, P. B., J. Exp. Biol, 28, 385 (1951).

    Google Scholar 

  10. Snell, G. D., Cancer Res., 17, 2 (1957).

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

GLYNN, J., BIANCO, A. & GOLDIN, A. Effect of “Methotrexate” and “Melphalan” on the Survival of Tumour and Skin Homo-grafts. Nature 198, 1003–1004 (1963). https://doi.org/10.1038/1981003b0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/1981003b0

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing